Search

Your search keyword '"Etanercept -- Product development"' showing total 9 results
Start Over Descriptor "Etanercept -- Product development" Topic business
9 results on '"Etanercept -- Product development"'

1. Clover Biopharmaceuticals Initiates Phase III Study of Etanercept Biosimilar Candidate SCB-808 in China

Subjects
Clinical trials, Rheumatoid factor, Biopharmaceuticals -- Product development, Etanercept -- Product development, Syringes, Biological products, Ankylosing spondylitis, Arthritis, Antiarthritic agents, Spondylitis, Biotechnology industries, Business, Business, international, Enbrel (Medication)
Abstract

BEIJING -- Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in a Phase III trial [...]

Published
2019

2. Clover Biopharmaceuticals Initiates Phase I Study of Etanercept Biosimilar Candidate SCB-808 in China

Subjects
Clinical trials, Rheumatoid factor, Biopharmaceuticals -- Product development, Biological products industry -- Product development, Etanercept -- Product development, Business, Business, international, Enbrel (Medication)
Abstract

CHENGDU, China -- Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in a Phase I trial of [...]

Published
2018

3. Sandoz Canada Regulatory Submission for Subsequent Entry Biologic Etanercept Accepted for Review by Health Canada

Subjects
Sandoz Canada Inc. -- Product development, Tumor necrosis factor, Pharmaceutical industry -- Product development, Etanercept -- Product development, Business, Business, international, News, opinion and commentary
Abstract

Jun 28, 2016 (Marketwired via COMTEX) -- BOUCHERVILLE, QC--(Marketwired - June 28, 2016) - Sandoz Canada announced today that Health Canada has accepted for review its regulatory submission for a [...]

Published
2016

4. One Year Data from Phase III Study Evaluating Oral OTEZLA[R] (apremilast) or Injectable etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at EADV

Subjects
Celgene Corp. -- Product development, Medical research, Psoriasis, Pharmaceutical industry -- Product development, Etanercept -- Product development, Business, Business, international, Otezla (Medication)
Abstract

Improvements in PASI scores and disease-related quality of life observed at week 16 were maintained at week 52 in patients randomized to OTEZLA at baseline and in patients who switched [...]

Published
2015

5. Positive Results from Phase III Study Evaluating Oral OTEZLA[R] (Apremilast) or Injectable Etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD

Subjects
Celgene Corp. -- Product development, Pharmaceutical industry -- Product development, Etanercept -- Product development, Business, Business, international, Otezla (Medication)
Abstract

Third phase III study with OTEZLA to demonstrate statistically significant improvements versus placebo for the primary and key secondary endpoints at week 16 More patients achieved a PASI-75 response at [...]

Published
2015

6. Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)

Subjects
Baxter International Inc. (Deerfield, Illinois) -- Product development, Psoriasis, Etanercept -- Product development, Medical test kit industry -- Product development, Medical equipment and supplies industry -- Product development, Business, News, opinion and commentary
Abstract

Company Advances Development as Part of Collaboration with Baxter International's Biopharmaceutical Business REDWOOD CITY, Calif., July 16, 2014 /PRNewswire/ -- http://www.coherus.com/ , Inc. announced the start of its Phase 3 [...]

Published
2014

7. Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Rheumatoid Arthritis

Subjects
Baxter International Inc. (Deerfield, Illinois) -- Product development, Etanercept -- Product development, Rheumatoid factor, Medical test kit industry -- Product development, Medical equipment and supplies industry -- Product development, Arthritis, Business, News, opinion and commentary
Abstract

Coherus Advances Development as Part of Collaboration with Daiichi Sankyo and Baxter REDWOOD CITY, Calif., June 23, 2014 /PRNewswire/ -- http://www.coherus.com/ , Inc. announced the start of its Phase 3 [...]

Published
2014

8. Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 Investigational Etanercept Biosimilar In Chronic Plaque Psoriasis RaPsOdy

Subjects
Psoriasis, Etanercept -- Product development, Biotechnology industry, Biological sciences, Business, Enbrel (Medication) -- Product development
Abstract

By a News Reporter-Staff News Editor at Biotech Business Week -- Coherus BioSciences , Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept [...]

Published
2014

9. Amgen Inc

Subjects
Wyeth Pharmaceuticals -- Alliances and partnerships -- Product development, Amgen Inc. -- Product development -- Alliances and partnerships, Etanercept -- Product development, Antirheumatic agents -- Product development, Methotrexate -- Product development, Pharmaceutical industry -- Alliances and partnerships -- Product development, Cooperative agreement for product development, Business, Chemicals, plastics and rubber industries, Enbrel (Medication) -- Product development
Abstract

AMGEN Inc. and Wyeth Pharmaceuticals, a division of Wyeth, announced that data from a long-term study of anti-tumor necrosis factor (anti-TNF) agent in rheumatoid arthritis showed no progression of joint [...]

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results